Cite
Wang B, Deng R, Hennig S, et al. Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer Chemother Pharmacol. 2021;doi: 10.1007/s00280-021-04342-x.
Wang, B., Deng, R., Hennig, S., Badovinac Crnjevic, T., Kaewphluk, M., Kågedal, M., Quartino, A. L., Girish, S., Li, C., & Kirschbrown, W. P. (2021). Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer chemotherapy and pharmacology, . https://doi.org/10.1007/s00280-021-04342-x
Wang, Bei, et al. "Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study." Cancer chemotherapy and pharmacology vol. (2021). doi: https://doi.org/10.1007/s00280-021-04342-x
Wang B, Deng R, Hennig S, Badovinac Crnjevic T, Kaewphluk M, Kågedal M, Quartino AL, Girish S, Li C, Kirschbrown WP. Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer Chemother Pharmacol. 2021 Sep 24; doi: 10.1007/s00280-021-04342-x. Epub 2021 Sep 24. PMID: 34559287.
Copy
Download .nbib